Genmab — December 2018

[Helge_LarsenPI-redaktør]

Apropos: https://borsen.dk/nyheder/virksomheder/artikel/1/373815/pensionskasser_gaar_imod_ambu-ledelsens_afloenning_man_kan_ogsaa_blive_i_tvivl_om_hvorvidt_endnu_flere_aktier_kan_blive_ved_med_at_vaere_en_motiverende_faktor.html?utm_source=forside&utm_campaign=nyhed_01

[Tandfeen-2]

Hvad er HOD?

[peter12]

Har den været linket ? http://www.biopharminsight.com/jjs-darzalex-phase-iii-first-line-mm-data-ash-bolster-drug’s-use-clinical-practice-immediately

[peter12]

HOD = dagens højeste

[peter12]

Interessant indblik i jnj-61186372 forsøger https://www.inspire.com/groups/american-lung-association-lung-cancer-survivors/discussion/jnj-372-cycle-2-and-beyond/

[Helge_LarsenPI-redaktør]

Nærmer Genmab sig et et købssignal:
http://www.proinvestor.com/debat/76559

[Raffles]

Artikel om Dara/Pom/Dexhttps://www.ncbi.nlm.nih.gov/pubmed/30536372/

[Helge_LarsenPI-redaktør]

Just a moment...

(www.proinvestor.com)

[Raffles]

Dara artikel: High-parameter mass cytometry evaluation of R/R MM patients treated with Dara demonstrates immune modulation as a novel mechanism of action https://www.ncbi.nlm.nih.gov/pubmed/30536810/

[E_L]

nice article on JNJ-372 @peter12 , so they are near 100 patients already. Looks like it is going to be more difficult to administer as dara though…

[bibob]

God formiddag fra : " 12 km over Paris. " to overskrifter på Børsen idag. " kapitalforvalter i kovending : smid alle dine aktier. og så Nordnet : 2018 var et aktieår. 2019 bliver bedre. :-). - sgu ikke noget at sige til at småinvestorer bliver rundtossede. Med så mange profeter der taler deres egen sag, er det vel bare at sige. " lad fornuften råde .

[Solsen]

I think the sc version of CD3 X CD20 have a chance to be easier administrated and tolerated than JNJ-372

[E_L]

that would be nice. the current trial is still IV though, isn't it?

[Bulder]

?? 372 is against lungcancer. cd3xcd20 is against B-cell malignancies. Why compare?

[Solsen]

No the CD20 x CD3 is sc in trial

[Solsen]

If its a generel problem with duobodies then I just mentioned it to calm down investor who would think it was the same issue with Genmabs own duobody in CD20XCD3.

[E_L]

we are just trying to see if our next blockbusters will have similar start-up problems lol

[E_L]

but when JNJ-372 is rolled out (when, not if ) the Dara infusion shares will be empty&available

[Solsen]

I belive JNJ have bought more options from HALO. If JNJ-372 is poven effective then they could use one of them in later trials.

[Sukkeralf]

As Jan has said before the problem with these new candidates is not if they work but if they are safe to patients